Study to Compare the Diopsys NOVA and LKC RETeval Devices

NCT05416268 — Not applicable, Completed, 20 participants, Diopsys, Inc.

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

An Objective Study to Compare the Diopsys NOVA and LKC RETeval Devices Using the Diopsys LID Electrodes and the LKC RETeval Self-Adhering Electrode Arrays

RegistryNCT05416268
StatusCompleted
PhaseNot applicable
Study typeInterventional; non randomized, crossover, masking: none, diagnostic
Enrollment20 (Actual)
SponsorDiopsys, Inc. (Industry)
ConditionsRetinal Disease
InterventionsElectroretinography (Diagnostic test)
Datesstart 2022-05-04, primary completion 2022-05-06, completion 2022-05-06, first posted 2022-06-13, last updated 2022-06-14
Locations1 site in United States

Related Papers Related Patents Related Grants Related Experts
All trials for Retinal Disease All trials of Electroretinography

-Summary

To compare the Diopsys NOVA and LKC RETeval Devices using the Diopsys Lid Electrodes and LKC RETeval Self-Adhering Electrode Arrays.

Expand all sections  ·  Collapse all

+Detailed description

This study is an open label, prospective study comparing the Diopsys NOVA and LKC RETeval devices using the Diopsys Lid Electrodes and the LKC RETeval Self-Adhering Electrode Arrays.

Subjects will receive the PhNR test three times using the Diopsys device and Diopsys Electrodes. Next, subjects will receive the FL Flicker test three times using the Diopsys device and Diopsys Electrodes. There will be a short break (10 to 15 minutes), then subjects will receive the PhNR test three times using the Diopsys device with LKC Electrode Arrays, followed by the FL Flicker test three times using the Diopsys device with the LKC electrode arrays. Subjects will receive another short break (5 to 10 minutes), then receive the PhNR test three times using the LKC device with the LKC electrode arrays, followed by the FL Flicker test three times using the LKC device with the LKC electrode arrays.

+Arms and interventions

ArmTypeInterventionsDescription
Diopsys NOVA and Diopsys ElectrodesOtherDiagnostic Test: ElectroretinographySubjects will receive the PhNR test three times using the Diopsys device and Diopsys Electrodes. Next, subjects will receive the FL Flicker test three times using the Diopsys device and Diopsys Electrodes.
Diopsys device with LKC Electrode ArraysOtherDiagnostic Test: ElectroretinographySubjects will receive the PhNR test three times using the Diopsys device with LKC Electrode Arrays, followed by the FL Flicker test three times using the Diopsys device with the LKC electrode arrays.
LKC device with the LKC electrode arraysOtherDiagnostic Test: ElectroretinographySubjects will receive the PhNR test three times using the LKC device with the LKC electrode arrays, followed by the FL Flicker test three times using the LKC device with the LKC electrode arrays.
  • Electroretinography (Diagnostic test), also known as Electrode Arrays: Two different electroretinogram devices (Diopsys NOVA and LKC RETeval Devices) will be evaluated with two different electrode arrays (Diopsys Lid Electrodes and LKC RETeval Self-Adhering Electrode Arrays).

+Outcome measures

Primary outcomes

  • PhNR Latency (ms) [Day 1]: Change in ERG PhNR Latency (ms) parameter

Secondary outcomes

  • FL Latency (ms) [Day 1]: Change in ERG FL Latency (ms) parameter

Other outcomes

  • PhNR B-wave Latency (ms) [Day 1]: Change in ERG PhNR B-wave Latency (ms) parameter
  • FL Magnitude (µV) [Day 1]: Change in ERG FL Magnitude (µV) parameter
  • PhNR A-Wave Latency (ms) [Day 1]: Change in ERG PhNR A-Wave Latency (ms) parameter
  • PhNR Ratio [Day 1]: Change in ERG PhNR Ratio parameter
  • PhNR amplitude (µV) [Day 1]: Change in ERG PhNR amplitude (µV) parameter
  • PhNR B-Wave Amplitude (µV) [Day 1]: Change in ERG PhNR B-Wave Amplitude (µV) parameter
  • PhNR A-Wave Amplitude (µV) [Day 1]: Change in ERG PhNR A-Wave Amplitude (µV) parameter
  • FL Phase (deg) [Day 1]: Change in ERG FL Phase (deg) parameter

+Eligibility

Sex: All, ages: 22 Years to any, accepts healthy volunteers

Inclusion Criteria:

* Male or female at least 22 years of age on day of enrollment
* BCVA letter score of 75 or better (Snellen equivalent of 20/32 or better) on day of enrollment
* Eyes are healthy/normal based on prior examinations, record review, and/or patient intake questions. Subject has not been diagnosed with any ocular pathology that could affect ERG results.
* Able to communicate well with the Investigator and able to understand and comply with the requirements of the study
* Informed of the nature of this study and has provided written, informed consent in accordance with institutional, local and national regulatory guidelines

Exclusion Criteria:

* A spherical refraction outside + 5.0 D and cylinder correction outside + 3.0 D on day of enrollment
* Intraocular surgery (except non-complicated cataract or refractive surgery performed more than 1 year before enrollment)
* Any prior macular or panretinal photocoagulation laser treatment
* History of ophthalmic or neurologic condition known to affect visual function
* Inability to obtain a reliable ERG test
* History of Diabetic retinopathy
* History of Glaucoma
* History of ARMD
* History of seizure disorder
* Has an open sore(s) or dermatological condition that may come in contact with the electrodes/electrode arrays
* In the opinion of the Investigator, is unlikely to comply with the study protocol

+Locations (1)

FacilityCityCountryStatus
NSU Oklahoma College of OptometryTahlequah, OklahomaUnited States

+Investigators